Annual Operating Expenses
$31.38 M
+$3.69 M+13.31%
December 31, 2023
Summary
- As of February 7, 2025, ATOS annual total operating expenses is $31.38 million, with the most recent change of +$3.69 million (+13.31%) on December 31, 2023.
- During the last 3 years, ATOS annual operating expenses has risen by +$16.77 million (+114.81%).
- ATOS annual operating expenses is now at all-time high.
Performance
ATOS Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$6.38 M
-$720.00 K-10.13%
September 30, 2024
Summary
- As of February 7, 2025, ATOS quarterly total operating expenses is $6.38 million, with the most recent change of -$720.00 thousand (-10.13%) on September 30, 2024.
- Over the past year, ATOS quarterly operating expenses has dropped by -$1.08 million (-14.50%).
- ATOS quarterly operating expenses is now -29.21% below its all-time high of $9.02 million, reached on December 31, 2023.
Performance
ATOS Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
ATOS Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +13.3% | -14.5% |
| 3 y3 years | +114.8% | +23.8% |
| 5 y5 years | +174.4% | +23.8% |
ATOS Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +52.9% | -29.2% | +34.5% |
| 5 y | 5-year | at high | +114.8% | -29.2% | +144.0% |
| alltime | all time | at high | +2810.7% | -29.2% | +6795.3% |
Atossa Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.38 M(-10.1%) |
| Jun 2024 | - | $7.11 M(+1.8%) |
| Mar 2024 | - | $6.98 M(-22.6%) |
| Dec 2023 | $31.38 M(+13.3%) | $9.02 M(+20.8%) |
| Sep 2023 | - | $7.47 M(-4.2%) |
| Jun 2023 | - | $7.79 M(+9.8%) |
| Mar 2023 | - | $7.10 M(-12.8%) |
| Dec 2022 | $27.69 M(+34.9%) | $8.14 M(-0.8%) |
| Sep 2022 | - | $8.21 M(+24.4%) |
| Jun 2022 | - | $6.59 M(+38.9%) |
| Mar 2022 | - | $4.75 M(-1.7%) |
| Dec 2021 | $20.52 M(+40.5%) | $4.83 M(-6.4%) |
| Sep 2021 | - | $5.16 M(-26.4%) |
| Jun 2021 | - | $7.00 M(+98.4%) |
| Mar 2021 | - | $3.53 M(-16.4%) |
| Dec 2020 | $14.61 M(-15.4%) | $4.23 M(+20.4%) |
| Sep 2020 | - | $3.51 M(-10.8%) |
| Jun 2020 | - | $3.94 M(+34.0%) |
| Mar 2020 | - | $2.94 M(+12.2%) |
| Dec 2019 | $17.27 M(+51.0%) | $2.62 M(-20.7%) |
| Sep 2019 | - | $3.30 M(-54.7%) |
| Jun 2019 | - | $7.29 M(+79.3%) |
| Mar 2019 | - | $4.06 M(+92.9%) |
| Dec 2018 | $11.43 M(+59.1%) | $2.11 M(-36.3%) |
| Sep 2018 | - | $3.31 M(-20.1%) |
| Jun 2018 | - | $4.14 M(+121.0%) |
| Mar 2018 | - | $1.87 M(+22.4%) |
| Dec 2017 | $7.19 M | $1.53 M(-25.5%) |
| Sep 2017 | - | $2.06 M(+8.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $1.90 M(+11.3%) |
| Mar 2017 | - | $1.70 M(-5.6%) |
| Dec 2016 | $7.25 M(-42.6%) | $1.80 M(+15.8%) |
| Sep 2016 | - | $1.56 M(-9.5%) |
| Jun 2016 | - | $1.72 M(-26.0%) |
| Mar 2016 | - | $2.33 M(-0.7%) |
| Dec 2015 | $12.63 M(+28.1%) | $2.34 M(-39.0%) |
| Sep 2015 | - | $3.84 M(+21.2%) |
| Jun 2015 | - | $3.17 M(-3.1%) |
| Mar 2015 | - | $3.27 M(+234.5%) |
| Dec 2014 | $9.86 M(-9.7%) | $978.40 K(-69.9%) |
| Sep 2014 | - | $3.25 M(+1.6%) |
| Jun 2014 | - | $3.20 M(+31.3%) |
| Mar 2014 | - | $2.44 M(-7.2%) |
| Dec 2013 | $10.92 M(+99.1%) | $2.62 M(-26.1%) |
| Sep 2013 | - | $3.55 M(+32.2%) |
| Jun 2013 | - | $2.69 M(+30.6%) |
| Mar 2013 | - | $2.06 M(+14.4%) |
| Dec 2012 | $5.49 M(+64.5%) | $1.80 M(+46.6%) |
| Sep 2012 | - | $1.23 M(-10.6%) |
| Jun 2012 | - | $1.37 M(+25.8%) |
| Mar 2012 | - | $1.09 M(-1.1%) |
| Dec 2011 | $3.33 M(+209.2%) | $1.10 M(-13.5%) |
| Sep 2011 | - | $1.27 M(+68.3%) |
| Jun 2011 | - | $756.90 K(+235.8%) |
| Mar 2011 | - | $225.40 K(-33.4%) |
| Dec 2010 | $1.08 M | $338.40 K(-29.1%) |
| Sep 2010 | - | $477.30 K(+142.0%) |
| Jun 2010 | - | $197.20 K(+113.0%) |
| Sep 2009 | - | $92.60 K |
FAQ
- What is Atossa Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Atossa Therapeutics?
- What is Atossa Therapeutics annual operating expenses year-on-year change?
- What is Atossa Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Atossa Therapeutics?
- What is Atossa Therapeutics quarterly operating expenses year-on-year change?
What is Atossa Therapeutics annual total operating expenses?
The current annual operating expenses of ATOS is $31.38 M
What is the all time high annual operating expenses for Atossa Therapeutics?
Atossa Therapeutics all-time high annual total operating expenses is $31.38 M
What is Atossa Therapeutics annual operating expenses year-on-year change?
Over the past year, ATOS annual total operating expenses has changed by +$3.69 M (+13.31%)
What is Atossa Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of ATOS is $6.38 M
What is the all time high quarterly operating expenses for Atossa Therapeutics?
Atossa Therapeutics all-time high quarterly total operating expenses is $9.02 M
What is Atossa Therapeutics quarterly operating expenses year-on-year change?
Over the past year, ATOS quarterly total operating expenses has changed by -$1.08 M (-14.50%)